Cytokinetics, Inc.  

(Public, NASDAQ:CYTK)   Watch this stock  
Find more results for CYTK
+0.17 (1.95%)
After Hours: 8.90 0.00 (0.00%)
Sep 27, 4:41PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.75 - 9.00
52 week 6.00 - 13.18
Open 8.77
Vol / Avg. 0.00/398,002.00
Mkt cap 350.56M
P/E     -
Div/yield     -
EPS -1.07
Shares 39.70M
Beta 1.29
Inst. own 67%
Oct 27, 2016
Q3 2016 Cytokinetics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 28, 2016
Q2 2016 Cytokinetics Inc Earnings Call
Jul 28, 2016
Q2 2016 Cytokinetics Inc Earnings Release
Jul 27, 2016
Cytokinetics Inc and Astellas Pharma Inc Announce Option Right for Tirasemtiv and Expansion of Global Collaboration for CK-2127107 in ALS - Webcast
Jul 12, 2016
Cytokinetics Inc at Cantor Fitzgerald Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -200.12% -130.86%
Operating margin -189.78% -130.53%
EBITD margin - -128.47%
Return on average assets -42.46% -30.22%
Return on average equity -87.33% -46.69%
Employees 100 -
CDP Score - -


280 E Grand Ave
United States - Map
+1-650-6243000 (Phone)
+1-650-6243010 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cytokinetics, Incorporated is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its lead drug candidate from its skeletal muscle contractility program, tirasemtiv, is a skeletal muscle troponin activator. The Company is developing CK-2127107, a skeletal muscle troponin activator. The Company has conducted approximately five Phase I clinical trials of CK-2127107. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is a cardiac muscle myosin activator. COSMIC-HF is a Phase II, double-blind, randomized, placebo-controlled, multicenter, clinical trial designed to assess the pharmacokinetics and tolerability of omecamtiv mecarbil dosed orally in patients with heart failure and left ventricular systolic dysfunction.

Officers and directors

Leonard Patrick Gage Ph.D. Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Robert I. Blum President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Sharon A. Barbari Chief Financial Officer, Executive Vice President - Finance
Age: 61
Bio & Compensation  - Reuters
Fady I. Malik M.D. Ph.D. Executive Vice President - Research and Development
Age: 50
Bio & Compensation  - Reuters
David W. Cragg Senior Vice President - Human Resources
Age: 59
Bio & Compensation  - Reuters
Bonnie A Charpentier Ph.D. Senior Vice President - Regulatory Affairs and Compliance
Age: 61
Bio & Compensation  - Reuters
Bradley Paul Morgan Senior Vice President - Drug Discovery and Early Development
Age: 55
Bio & Compensation  - Reuters
Andrew A. Wolff M.D. Senior Vice President - Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Caryn Gordon McDowell J.D. Chief Compliance Officer, Vice President, General Counsel
Age: 46
Bio & Compensation  - Reuters
Edward M. Kaye M.D. Director
Age: 67
Bio & Compensation  - Reuters